In vitro and in vivo, evodiamine and rutaecarpine may inhibit the biosynthesis of allergy-related cytokines (TNF-α and IL-4) in mast cells and basophils, suggesting that they may be effective against IgE-induced allergic diseases such as atopic dermatitis and rhinitis (Shin et al., 2007). Here, TNF is linked to allergic disease.